Psoriasis (Moderate to Severe) | Decision Base | US | 2015
With the Entry of New Oral and Biological Agents, Where Are the Remaining Areas of Opportunity in an Increasingly Crowded Market?
Affecting more than three million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial opportunity. However, competition is set to intensify with the recent launch of the first approved IL-17 inhibitor, secukinumab (Novartis’s Cosentyx), and other highly efficacious biologics in the late-stage pipeline. These agents’ efficacy on more-stringent measures of response (i.e., PASI 90 and PASI 100 response rates) and superior efficacy to current agents in head-to-head studies will significantly raise the bar for psoriasis therapies.
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
